Home » Authors » Douglas Merrill

Articles by Douglas Merrill

Insurance Costs Prompt Mass Exodus From LION Bioscience

Oct. 20, 2004

By Douglas Merrill

Preclinical Alzheimer's Data Trigger Change At Sirenade

Oct. 20, 2004

By Douglas Merrill

Public, Private Sectors At Odds Over German Biotech Direction

Sep. 29, 2004

By Douglas Merrill

Public, Private Sectors At Odds Over German Biotech Direction

Sep. 29, 2004

By Douglas Merrill

Intercell's Start-Up Biovertis Receives EUR12M In Series A

Sep. 8, 2004

By Douglas Merrill

Intercell's Start-Up Biovertis Receives EUR12M In Series A

Sep. 8, 2004

By Douglas Merrill

Intercell's Hepatitis C Vaccine Gets Positive Phase II Results

July 28, 2004

By Douglas Merrill

Intercell's Hepatitis C Vaccine Gets Positive Phase II Results

July 28, 2004

By Douglas Merrill

Trying To Open German Biotech Market, Epigenomics Seeks IPO

July 7, 2004

By Douglas Merrill

Trying To Open German Biotech Market, Epigenomics Seeks IPO

July 7, 2004

By Douglas Merrill

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 4, 2024.
In muscular dystrophies, gene therapies race the clock
BioWorld
Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular...
Bridgebio, with FDA approval, faces Pfizer in ATTR
BioWorld
With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry...
Phase III AMD miss leaves BLA Outlook same with bevacizumab
BioWorld
Outlook Therapeutics Inc. is forging onward with plans to resubmit the BLA for ONS-5010, an ophthalmic version of Avastin (bevacizumab, Roche AG), after a missed...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.